JP2023531709A5 - - Google Patents

Info

Publication number
JP2023531709A5
JP2023531709A5 JP2022579835A JP2022579835A JP2023531709A5 JP 2023531709 A5 JP2023531709 A5 JP 2023531709A5 JP 2022579835 A JP2022579835 A JP 2022579835A JP 2022579835 A JP2022579835 A JP 2022579835A JP 2023531709 A5 JP2023531709 A5 JP 2023531709A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
alkyl
isotopolog
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022579835A
Other languages
English (en)
Japanese (ja)
Other versions
JP7778095B2 (ja
JP2023531709A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038625 external-priority patent/WO2021262812A1/en
Publication of JP2023531709A publication Critical patent/JP2023531709A/ja
Publication of JP2023531709A5 publication Critical patent/JP2023531709A5/ja
Application granted granted Critical
Publication of JP7778095B2 publication Critical patent/JP7778095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022579835A 2020-06-24 2021-06-23 セレブロン結合化合物、その組成物及びそれによる治療方法 Active JP7778095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043612P 2020-06-24 2020-06-24
US63/043,612 2020-06-24
PCT/US2021/038625 WO2021262812A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Publications (3)

Publication Number Publication Date
JP2023531709A JP2023531709A (ja) 2023-07-25
JP2023531709A5 true JP2023531709A5 (https=) 2024-06-18
JP7778095B2 JP7778095B2 (ja) 2025-12-01

Family

ID=79032406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579835A Active JP7778095B2 (ja) 2020-06-24 2021-06-23 セレブロン結合化合物、その組成物及びそれによる治療方法

Country Status (9)

Country Link
US (2) US11739075B2 (https=)
EP (1) EP4171568B1 (https=)
JP (1) JP7778095B2 (https=)
KR (1) KR20230027213A (https=)
CN (1) CN115955979B (https=)
AR (1) AR122725A1 (https=)
ES (1) ES3048462T3 (https=)
TW (1) TW202216681A (https=)
WO (1) WO2021262812A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
WO2022262782A1 (zh) * 2021-06-17 2022-12-22 南京明德新药研发有限公司 戊二酰亚胺取代的异噁唑稠环化合物及其应用
JP2024534223A (ja) 2021-09-01 2024-09-18 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Bcl-2ファミリータンパク質を分解する化合物及びその医薬的な応用
AU2023278399A1 (en) 2022-06-02 2024-12-19 Xizang Haisco Pharmaceutical Co., Ltd. Compound for inhibiting or degrading bcl6 and use thereof in pharmaceutics
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 3-苯基丙基胺衍生物
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
WO2008101030A1 (en) * 2007-02-13 2008-08-21 The Regents Of The University Of California Methods for amplifying steroid hormone effects
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
WO2015179438A1 (en) * 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110317192A (zh) * 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物
CN113453681B (zh) 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物及使用它们的治疗方法
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Similar Documents

Publication Publication Date Title
JP2023531709A5 (https=)
JP2023533203A5 (https=)
JP2023531495A5 (https=)
JP2022512482A5 (https=)
JP2024520481A5 (https=)
JP2019094345A5 (https=)
JP2020506951A5 (https=)
JP2021535207A5 (https=)
SI2743266T1 (en) Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis
JP2022520448A5 (https=)
JP2019500352A5 (https=)
JP2021523159A5 (https=)
JP2011509309A5 (https=)
JP2019518766A5 (https=)
JP2015516420A5 (https=)
JP2018504437A5 (https=)
JP2014528464A5 (https=)
JP2020507589A5 (https=)
JP2022514347A5 (https=)
JP2021528427A5 (https=)
JP2022511477A5 (https=)
JP2020063289A5 (https=)
JP2010533699A5 (https=)
JP2014514290A5 (https=)
JP2024526191A5 (https=)